Welcome to the UPF Digital Repository

Impact of biological agents on postsurgical complications in inflammatory bowel disease: a multicentre study of geteccu

Show simple item record

dc.contributor.author García, María José
dc.contributor.author González-Vivó, María
dc.contributor.author Gisbert, Javier P.
dc.contributor.author The Young Group of Geteccu
dc.date.accessioned 2022-06-21T06:49:03Z
dc.date.available 2022-06-21T06:49:03Z
dc.date.issued 2021
dc.identifier.citation García MJ, Rivero M, Miranda-Bautista J, Bastón-Rey I, Mesonero F, Leo-Carnerero E, et al. Impact of biological agents on postsurgical complications in inflammatory bowel disease: a multicentre study of geteccu. J Clin Med. 2021 Sep 26; 10(19): 4402. DOI: 10.3390/jcm10194402
dc.identifier.issn 2077-0383
dc.identifier.uri http://hdl.handle.net/10230/53549
dc.description.abstract Background: The impact of biologics on the risk of postoperative complications (PC) in inflammatory bowel disease (IBD) is still an ongoing debate. This lack of evidence is more relevant for ustekinumab and vedolizumab. Aims: To evaluate the impact of biologics on the risk of PC. Methods: A retrospective study was performed in 37 centres. Patients treated with biologics within 12 weeks before surgery were considered "exposed". The impact of the exposure on the risk of 30-day PC and the risk of infections was assessed by logistic regression and propensity score-matched analysis. Results: A total of 1535 surgeries were performed on 1370 patients. Of them, 711 surgeries were conducted in the exposed cohort (584 anti-TNF, 58 vedolizumab and 69 ustekinumab). In the multivariate analysis, male gender (OR: 1.5; 95% CI: 1.2-2.0), urgent surgery (OR: 1.6; 95% CI: 1.2-2.2), laparotomy approach (OR: 1.5; 95% CI: 1.1-1.9) and severe anaemia (OR: 1.8; 95% CI: 1.3-2.6) had higher risk of PC, while academic hospitals had significantly lower risk. Exposure to biologics (either anti-TNF, vedolizumab or ustekinumab) did not increase the risk of PC (OR: 1.2; 95% CI: 0.97-1.58), although it could be a risk factor for postoperative infections (OR 1.5; 95% CI: 1.03-2.27). Conclusions: Preoperative administration of biologics does not seem to be a risk factor for overall PC, although it may be so for postoperative infections.
dc.format.mimetype application/pdf
dc.language.iso eng
dc.publisher MDPI
dc.rights Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https:// creativecommons.org/licenses/by/ 4.0/).
dc.rights.uri http://creativecommons.org/licenses/by/ 4.0/
dc.title Impact of biological agents on postsurgical complications in inflammatory bowel disease: a multicentre study of geteccu
dc.type info:eu-repo/semantics/article
dc.identifier.doi http://dx.doi.org/10.3390/jcm10194402
dc.subject.keyword Crohn’s disease
dc.subject.keyword Anti-TNF
dc.subject.keyword Inflammatory bowel disease
dc.subject.keyword Postoperative complications
dc.subject.keyword Preoperative therapy
dc.subject.keyword Surgery
dc.subject.keyword Ulcerative colitis
dc.subject.keyword Ustekinumab
dc.subject.keyword Vedolizumab
dc.rights.accessRights info:eu-repo/semantics/openAccess
dc.type.version info:eu-repo/semantics/publishedVersion

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Search DSpace


Advanced Search

Browse

My Account

Statistics

Compliant to Partaking